Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

US-based gene therapy developer 4D Molecular Therapeutics (4DMT) refiled for an initial public offering on Tuesday, giving Berkeley Catalyst Fund, a venture unit aligned with University of California, the chance to exit. The company has filed to raise up to $75m in an offering on the Nasdaq Global Market, the same market where it originally filed for a $100m IPO in September 2019 before withdrawing that application in July. Goldman Sachs, BofA Securities and Evercore Group are the underwriters. 4DMT is developing drugs based on adeno-associated viruses it has invented. The IPO takings will fund progress of drug candidates including 4D-310 and 4D-125, treatments for a rare genetic disorder called Fabry disease and X-linked retinitis pigmentosa, which causes blindness – both of which are in phase 1/2 clinical trials. Hedge fund manager Viking Global Investors led a $75m series C round for 4DMT five months ago that included Berkeley Catalyst Fund, as well as Pfizer Ventures and Chiesi Ventures, which invested on behalf of pharmaceutical firms Pfizer and Chiesi. MiraeAsset, Cystic Fibrosis Foundation, Amzak Health, Longevity Vision Fund, BVF Partners, Arrowmark Partners, Ridgeback Capital Investments, Perceptive Advisors, Pappas Capital, Casdin Capital, Longevity Vision Fund, Octagon Investments and Quad Investment Management also took part. The company had secured $90m in a 2018 series B round featuring Berkeley Catalyst Fund, Pfizer Ventures, Chiesi Ventures, Viking Global, CureDuchenne Ventures, ArrowMark Partners, Janus Henderson Investors, Biotechnology Value Fund, MiraeAsset, Perceptive Advisors and Ridgeback Capital Investments. The series B round came in the wake of at least $21.6m in earlier funding from investors including Cystic Fibrosis Foundation Therapeutics. Viking Global is 4DMT’s largest investor, with a 16.9% stake, followed by Pfizer (9.7%) and BVF (5.4%). – A version of this article first appeared on our sister site, Global Corporate Venturing.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?